Investor Presentaiton
For personal use only
TLX250-CDx / TLX250 overview
An exciting target, with potential application beyond kidney cancer
Target: Carbonic Anhydrase IX (CAIX / CA9)
.
Indication: Kidney cancer (clear cell renal cell carcinoma, ccRCC)
Target:
CAIX / CA9
Dx
(TLX 250-CDX)
Tx
(TLX250)
Development status:
•
TLX 250-CDx: Phase III ZIRCON diagnostic imaging study
nearing completion
Targeting
molecule
Antibody
Antibody
.
TLX250: Phase II STARLITE 1 & 2 therapeutic studies
(in combination with immunotherapy) initiated
Targeting
agent
DFO-
girentuximab
DOTA-
girentuximab
Rationale:
.
CA9 is over-expressed in mutated ccRCC and many hypoxic solid
tumors, with low expression in most normal tissue
Radionuclide
89 Zr
177 Lu
Tumour hypoxia correlates with progression and resistance
to therapy
•
Potential for targeted radiation to enhance the effect of
existing ccRCC therapies such as immunotherapy
Limited competition in imaging, optimises surgical management
Telix Pharmaceuticals Limited (ASX: TLX)
39
TELIX
PHARMACEUTICALSView entire presentation